Hybrid Stroke Rehab With Mirror Priming

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-80
SponsorI-Shou University

About this trial

This trial aims to examine the effects of enhanced mirror priming, overcoming the limitations of traditional mirror therapy, to achieve optimization and personalized intervention.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

A first-ever unilateral stroke ≥3 months

Age between 20 and 80 years

Baseline Fugl-Meyer Assessment Upper Extremity (FMA-UE) score >10

No severe spasticity in any joints of the affected arm

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • Mirror priming

    Behavioral

    During the mirror priming process, the movement images of the participant's unaffected limb are mirrored to the affected side to provide visual feedback.

  • Conventional therapy

    Behavioral

    During conventional therapy, the participants typically receive interventions targeting the upper and lower limbs in addition to cognitive practice.

Treatment groups

81 Participants
are divided into 3 treatment groups
Group A: High-dose enhanced mirror priming groupExperimental treatment 2 interventions
Group B: Low-dose enhanced mirror priming groupExperimental treatment 2 interventions
Group C: Active control groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Fugl-Meyer Assessment

Time frame
Baseline, 2 weeks, 4 weeks, 1 month, and 3 months post-intervention.

Secondary outcomes

1

Grip and pinch power

Time frame
Baseline, 4 weeks, 1 month, and 3 months post-intervention.
2

Revised Nottingham Sensory Assessment

Time frame
Baseline, 4 weeks, 1 month, and 3 months post-intervention.
3

Berg Balance Scale

Time frame
Baseline, 4 weeks, 1 month, and 3 months post-intervention.
4

Montreal Cognitive Assessment

Time frame
Baseline, 4 weeks, 1 month, and 3 months post-intervention.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.